SENSORS INCORPORATING ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
    117.
    发明申请
    SENSORS INCORPORATING ANTIBODIES AND METHODS OF MAKING AND USING THE SAME 有权
    包含抗体的传感器及其制造和使用方法

    公开(公告)号:US20120122736A1

    公开(公告)日:2012-05-17

    申请号:US13201181

    申请日:2010-02-11

    CPC classification number: G01N33/5438 Y10T29/41

    Abstract: A sensor comprising an electronic circuit electrically coupled to a type III-V semiconductor material, for example indium arsenide (InAs) and an antibody contacting the type III-V semiconductor material. The sensor produces measurable N changes in the electrical properties of the semiconductor upon antibody-antigen binding events. Electrical properties measurable by the electronic device may include resistivity, capacitance, impedance, and inductance. A method of detecting an antigen using sensors of the invention. A method of detecting a reaction of an analyte to a stimulus using sensors of the invention. Sensor arrays comprising multiple sensors of the invention.

    Abstract translation: 一种传感器,包括电耦合到III-V族半导体材料的电子电路,例如砷化铟(InAs)和与III-V族半导体材料接触的抗体。 传感器在抗体 - 抗原结合事件时产生半导体电性能的可测量的N变化。 电子设备可测量的电气特性可包括电阻率,电容,阻抗和电感。 使用本发明的传感器检测抗原的方法。 使用本发明的传感器检测分析物与刺激物的反应的方法。 传感器阵列包括本发明的多个传感器。

    MARKERS FOR ENDOMETRIAL CANCER
    118.
    发明申请
    MARKERS FOR ENDOMETRIAL CANCER 有权
    子宫内膜癌标志物

    公开(公告)号:US20120122726A1

    公开(公告)日:2012-05-17

    申请号:US13386536

    申请日:2010-07-23

    Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

    Abstract translation: 本发明涉及令​​人惊奇的发现:对应于ACAA1,AP1M2,CGN,DDR1,EPS8L2,FASTKD1,GMIP,IKBKE,P2RX4,P4HB,PHKG2,PPFIBP2,PPP1R16A,RASSF7,RNF183,SIRT6,TJP3,EFEMP2,S0CS2, 与对照样品相比,DCN与子宫内膜癌患者相比差异表达,因此可用于检测子宫内膜癌。 特别地,这些具有优异的敏感性,特异性和/或分离受影响的非受影响个体的能力的生物标志物。 此外,发明人发现与对照值相比,这些生物标志物在原发性子宫内膜癌肿瘤组织中的差异表达与子宫液样品中的表达水平相关。 因此,这些生物标志物是稳健的,因为它们被发现在受影响个体的几种不同类型的样品中差异表达。

    SCREENING OF BIOPOLYMERS
    119.
    发明申请
    SCREENING OF BIOPOLYMERS 审中-公开
    生物聚合物筛选

    公开(公告)号:US20120122711A1

    公开(公告)日:2012-05-17

    申请号:US13384510

    申请日:2010-07-15

    CPC classification number: G01N33/6845

    Abstract: Described herein are inventive compositions and methods relating to sampling of biopolymers and, in particular, to fractional sampling of biopolymers. In one aspect, embodiments are generally related to unique biopolymer species where a fraction of each biopolymer species contains a cleavable linker. The biopolymer species may, in some embodiments, be attached to a surface. For example, the biopolymer species may be attached to beads. In some embodiments, a portion of a unique biopolymer species may be sampled by cleaving the cleavable linker. In some cases, the sample may be analyzed to determine the sequence of the biopolymer.

    Abstract translation: 本文描述了与生物聚合物的取样有关的本发明组合物和方法,特别是生物聚合物的分数取样。 在一个方面,实施方案通常涉及独特的生物聚合物种类,其中每个生物聚合物种类的一部分含有可切割的连接体。 在一些实施方案中,生物聚合物物质可附着于表面。 例如,生物聚合物物质可以连接到珠粒上。 在一些实施方案中,可以通过切割可切割接头来采样一部分独特的生物聚合物种类。 在一些情况下,可以分析样品以确定生物聚合物的顺序。

Patent Agency Ranking